Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction.

作者信息

Dardikh M, Albert T, Masereeuw R, Oldenburg J, Novakova I, van Heerde W L, Verbruggen B

出版信息

J Thromb Haemost. 2012 Apr;10(4):706-8. doi: 10.1111/j.1538-7836.2012.04645.x.

DOI:10.1111/j.1538-7836.2012.04645.x

PMID:22284849

Abstract

摘要

相似文献

Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction.

J Thromb Haemost. 2012 Apr;10(4):706-8. doi: 10.1111/j.1538-7836.2012.04645.x.

Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion.

J Thromb Haemost. 2016 Oct;14(10):2073-2074. doi: 10.1111/jth.13435. Epub 2016 Oct 5.

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

J Thromb Haemost. 2014 Nov;12(11):1788-800. doi: 10.1111/jth.12723. Epub 2014 Oct 10.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.

J Thromb Haemost. 2015 Jun;13(6):967-77. doi: 10.1111/jth.12911. Epub 2015 Apr 23.

Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.

J Thromb Haemost. 2015 Apr;13(4):540-7. doi: 10.1111/jth.12846. Epub 2015 Feb 27.

Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?

J Thromb Haemost. 2012 Oct;10(10):2194-6. doi: 10.1111/j.1538-7836.2012.04871.x.

How I treat inhibitors in haemophilia.

Haemophilia. 2012 Jul;18 Suppl 4:48-53. doi: 10.1111/j.1365-2516.2012.02829.x.

The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.

J Thromb Haemost. 2015 Mar;13(3):370-9. doi: 10.1111/jth.12816. Epub 2015 Feb 13.

Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.

Haemophilia. 2012 May;18(3):e75-7. doi: 10.1111/j.1365-2516.2012.02776.x. Epub 2012 Mar 8.

Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.

Thromb Haemost. 2010 Nov;104(5):931-40. doi: 10.1160/TH10-03-0151. Epub 2010 Sep 13.

引用本文的文献

Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate.

Eur J Drug Metab Pharmacokinet. 2024 Mar;49(2):191-205. doi: 10.1007/s13318-024-00876-6. Epub 2024 Feb 17.

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.

Br J Clin Pharmacol. 2022 Jun;88(6):2757-2768. doi: 10.1111/bcp.15185. Epub 2022 Jan 15.

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.

J Thromb Haemost. 2020 Dec;18(12):3222-3231. doi: 10.1111/jth.15106. Epub 2020 Oct 21.

Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15.

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

J Thromb Haemost. 2017 Oct;15(10):1971-1976. doi: 10.1111/jth.13795. Epub 2017 Sep 14.

Progress toward inducing immunologic tolerance to factor VIII.

Blood. 2013 May 30;121(22):4449-56. doi: 10.1182/blood-2013-01-478669. Epub 2013 Mar 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验